DOCS
Doximity, Inc.43.80
-0.85-1.9%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
FY Q2 '26
Upsell timing shift clarified
Q&A clarified Q2's blowout beat reflected earlier upsells from AI-optimized integrated programs (40% of bookings) and portal insights, pulling forward dollars for smoother back-half CY2025 growth at 14% YoY versus historical budget flushes—explaining Q3's tempered 7% guide. Management was cautious on calendar 2026 budgets amid policy uncertainty like D2C ad shifts and Trump Rx pricing, yet highlighted tailwinds, agency-driven 100% SMB surge, and high engagement. AI momentum accelerated: 50% QoQ user growth, tripled Scribe users, top health systems adopting. They're winning blinded tests versus rivals. Watch upfront pacing and AI monetization.
Key Stats
Market Cap
8.25BP/E (TTM)
35.04Basic EPS (TTM)
1.25Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Doximity crushed Q2 FY2026 ended September 30, 2025, with revenue jumping 23% y/y to $168.5M on subscription strength, while operating income soared 20% y/y to $63.7M and diluted EPS climbed to $0.31 from $0.22 (reconciles to 200.7M shares). Gross margin held steady at 90%, yet R&D and sales expenses rose on hiring and marketing push. Free cash flow hit $151.7M (operating cash $156.0M minus $4.3M capex); cash plus marketable securities stood at $878.4M despite $144.2M stock repurchases, with $279.8M authorized remaining. Closed Pathway acquisition in July 2025 for $36.3M (cash/RSUs), recognizing $17.0M goodwill and $18.7M developed technology (5-year life). Cash stays king. Litigation clouds persist.
8-K
Q2 revenue up 23%
8-K
Annual meeting votes approved
Doximity stockholders overwhelmingly approved key items at its August 28, 2025 Annual Meeting, with 97.51% of votes present. They elected Jeff Tangney and Kira Wampler as Class I directors, ratified Deloitte & Touche as auditors for fiscal 2026, and backed executive pay on a non-binding basis. Votes sailed through. Tangney drew minor withholds, but support held firm.
8-K
GC Chaloemtiarana exits, Vaughan steps in
Doximity's General Counsel Jennifer Chaloemtiarana steps down effective August 29, 2025, with John Vaughan immediately assuming her roles as General Counsel, Corporate Secretary, and Chief Compliance Officer. She stays on as advisor through November 17. Smooth transition. Post-employment terms follow her 2020 offer letter.
10-Q
Q1 FY2026 results
Doximity posted revenue of $145.9M for Q1 FY2026 ended June 30, 2025, up 15% y/y from $126.7M, with gross profit climbing to $130.1M at steady 89% margin. Operating income rose to $54.5M from $46.1M y/y, boosted by subscription growth to $137.9M, while diluted EPS improved to $0.27 from $0.21 on 201K shares. Operating cash flow hit $62.1M, yielding $60.1M free cash flow (derived); cash and equivalents stood at $137.3M with $703.7M marketable securities after $122M buybacks. Paid $5.2M settling AMiON contingent earn-out. Securities suits over user metrics loom.
IPO
Website
Employees
Sector
Industry
DCGO
DocGo Inc.
0.91-0.01
DH
Definitive Healthcare Corp.
2.29-0.01
DOCU
DocuSign, Inc.
67.58-0.61
DRIO
DarioHealth Corp.
12.05+0.05
GDRX
GoodRx Holdings, Inc.
2.76+0.05
HIMS
Hims & Hers Health, Inc.
36.86+0.61
HNGE
Hinge Health, Inc.
48.41-0.09
LFMD
LifeMD, Inc.
3.42+0.15
OPRX
OptimizeRx Corporation
12.77-0.41
TDOC
Teladoc Health, Inc.
7.41+0.07